证券代码：833230 证券简称：欧康医药 公告编号：2025-003 成都欧康医药股份有限公司舆情管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、审议及表决情况 成都欧康医药股份有限公司于 2025 年 1 月 22 日召开第四届董事会第六 次会议，审议通过《关于制定<舆情管理制度>的议案》，表决结果：同意 9 票， 反对 0 票，弃权 0 票。本议案无需提交股东大会审议。 成都欧康医药股份有限公司 舆情管理制度 第一章 总则 第一条 为提高成都欧康医药股份有限公司（以下简称"公司"）应对各 类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公 司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法 权益，根据《北京证券交易所股票上市规则（试行）》等有关法律法规、规范 性文件及《成都欧康医药股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，并结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报 ...

证券代码：833230 证券简称：欧康医药 公告编号：2025-004 成都欧康医药股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2025 年 1 月 17 日以书面方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 独立董事胥兴军、张霜、赵宇霆因工作原因以通讯方式参与表决。 董事伍丽因工作原因以通讯方式参与表决。 二、议案审议情况 （一）会议召开情况 1.会议召开时间：2025 年 1 月 22 日 具体内容详见公司于 2025 年 1 ...

Financial Performance - The net profit attributable to shareholders for 2024 is projected to be between ¥22 million and ¥25 million, representing an increase of 31.97% to 49.97% compared to the previous year's ¥16.67 million[3]. - The net profit after deducting non-recurring gains and losses is expected to be between ¥20 million and ¥22.5 million, reflecting a growth of 45.18% to 63.33% from last year's ¥13.78 million[3]. Product Development - The company has made significant progress in developing new products, particularly the Zhi Shi series, which has contributed to the revenue growth in the domestic market[4]. - The company has expanded its product applications into the food additive sector, attracting new clients and further boosting net profit[4]. Caution for Investors - The financial data presented is preliminary and has not been audited, emphasizing the need for investors to exercise caution[5].

证券代码：833230 证券简称：欧康医药 公告编号：2024-095 成都欧康医药股份有限公司 关于完成工商变更登记并取得营业执照的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）实施 2024 年股权激励计划， 向激励对象定向发行公司普通股股票，首次授予人数 34 人，共授予限制性股票 163.59 万股，已完成股份登记，具体内容详见公司于 2024 年 11 月 18 日在北京 证券交易所信息披露平台（www.bse.cn）披露的《2024 年股权激励计划限制性 股票首次授予结果公告》（公告编号：2024-093）。 二、变更登记与备案情况 目前，公司已经完成工商变更登记，并于 2024 年 12 月 5 日取得成都市市场 监督管理局换发的《营业执照》。本次工商变更完成后，公司注册资本由 75,631,404 元变更为 77,267,304 元。除以上变更外，《营业执照》记载的其他工 商登记事项未发生变更。变更后的营业执照信息如下： ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-094 成都欧康医药股份有限公司股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 438,744 股，占公司总股本 0.57%，可交易时 间为 2024 年 11 月 22 日。 二、本次股票解除限售的明细情况及原因 单位：股 | 序号 | 股东姓名 | 是否为控 股股东、 | 董事、监 事、高级 | 本次解 | 本次解除 | 本次解除 限售股数 | 尚未解除 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 实际控制 | | 限售原 | 限售登记 | | 限售的股 | | | 或名称 | 人或其一 | 管理人员 | 因 | 股票数量 | 占公司总 | 票数量 | | | | 致行动人 | 任职情况 | | | 股本比例 | | | 1 | 陈德芬 | 否 | 原董事、 | B | 228,472 | 0.30% | 0 | | ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-093 成都欧康医药股份有限公司 2024 年股权激励计划限制性股票首次授予结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、限制性股票授予结果 （一）实际授予基本情况 1、授予日：2024 年 9 月 25 日 6、股票来源：公司向激励对象定向发行的本公司 A 股普通股股票 | （二）实际授予登记的限制性股票在各激励对象间的分配情况如下表： | | --- | | | | 获授的限制性股 | 占本次激励计划 | 占本次激励计划 | | --- | --- | --- | --- | --- | | 姓名 | 职务 | 票数量（万股） | 授出限制性股票 | 草案公告日股本 | | | | | 总数的比例 | 总额的比例 | | 赵卓君 | 董事长、总经理 | 11.09 | 5.73% | 0.15% | | 伍丽 | 董事、副总经理 | 7.39 | 3.82% | 0.10% | | 贾秀蓉 | 董事 | 5.55 | 2 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a favorable outlook compared to the market index [8]. Core Insights - The company specializes in the research, production, and sales of plant extracts, focusing on natural vitamin P compounds such as quercetin, rutin, diosmin, and hesperidin. It has established itself as a standard-setting organization for several products in the industry [1]. - In the first nine months of 2024, the company achieved a revenue of 223.83 million yuan, representing a year-on-year increase of 31.83%. The net profit attributable to shareholders was 19.53 million yuan, up 54.23% year-on-year [5]. - The company reported a gross margin of 20.52% for the first nine months of 2024, an increase of 4.08 percentage points compared to the previous year, and a net margin of 8.60%, up 1.15 percentage points [5]. Financial Summary - **Revenue (in million yuan)**: - 2020: 191.45 - 2021: 300.86 - 2022: 269.44 - 2023: 242.81 - Year-on-year growth: 2021 (+57.14%), 2022 (-10.44%), 2023 (-9.88%) [1] - **Net Profit (in million yuan)**: - 2020: 22.66 - 2021: 41.92 - 2022: 33.66 - 2023: 16.67 - Year-on-year growth: 2021 (+85.00%), 2022 (-19.69%), 2023 (-50.48%) [1] - **Gross Margin**: - 2020: 24.16% - 2021: 24.30% - 2022: 22.51% - 2023: 16.25% [1] - **Return on Equity (ROE)**: - 2020: 22.68% - 2021: 32.71% - 2022: 12.61% - 2023: 4.26% [1] - **Earnings per Share (in yuan)**: - 2020: 0.30 - 2021: 0.55 - 2022: 0.45 - 2023: 0.22 [1] - **Price-to-Earnings Ratio (P/E)**: - 2020: 7.62 - 2021: 21.97 - 2022: 22.76 - 2023: 64.65 [1] Market Data - As of November 8, 2024, the closing price of the company's stock is 23.75 yuan, with a total share capital of 75.63 million shares and a net asset value of 409.17 million yuan [3].

证券代码：833230 证券简称：欧康医药 公告编号：2024-091 成都欧康医药股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2024 年 10 月 22 日以书面方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：全体监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 独立董事胥兴军、张霜因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年第三季度报告>的议案》 1.议案内容： 根 ...

Financial Performance - Operating revenue for the first nine months of 2024 reached CNY 223,826,491.38, a 31.83% increase from CNY 169,781,662.69 in the same period of 2023[4] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 19,526,091.61, up 54.23% from CNY 12,660,076.62 year-on-year[4] - Basic earnings per share increased by 52.94% to CNY 0.26 for the first nine months of 2024, compared to CNY 0.17 in the same period of 2023[4] - In Q3 2024, operating revenue was CNY 91,517,316.49, representing a 59.01% increase from CNY 57,555,852.54 in Q3 2023[4] - Net profit attributable to shareholders in Q3 2024 surged by 135.22% to CNY 5,678,588.17, compared to CNY 2,414,185.81 in Q3 2023[4] - Total operating revenue for the first nine months of 2024 reached ¥223,826,491.38, a significant increase of 31.8% compared to ¥169,781,662.69 in the same period of 2023[21] - Total operating costs for the same period were ¥201,402,456.95, up 26.6% from ¥159,181,541.57 in 2023[21] - Net profit for the first nine months of 2024 reached ¥21,167,587.14, a significant increase from ¥12,764,111.63 in the same period of 2023, representing a growth of approximately 66.5%[24] - Operating profit for the first nine months of 2024 was ¥25,593,540.83, up from ¥12,889,004.88 in 2023, reflecting an increase of approximately 98.5%[23] Cash Flow - Cash flow from operating activities showed a significant decline, with a net outflow of CNY 12,729,953.33, down 173.88% from a net inflow of CNY 17,230,872.40 in the previous year[4] - The company’s cash and cash equivalents decreased by 63.18% to CNY 18,967,926.25 due to the utilization of raised funds for projects and payments for raw materials[5] - Cash inflow from sales of goods and services was CNY 234,019,482.97, up from CNY 197,947,413.73 in the same period of 2023, reflecting a growth of about 18.2%[25] - The cash outflow for purchasing goods and services was CNY 232,097,518.50, compared to CNY 165,063,324.53 in the previous year, indicating an increase of approximately 40.5%[25] - Cash inflow from investment activities totaled CNY 266,774,071.59, up from CNY 200,206,644.85 in the previous year, marking an increase of about 33.2%[26] - The net cash flow from investment activities was -CNY 13,023,463.82, an improvement from -CNY 39,798,265.70 in the same period of 2023[26] - Cash inflow from financing activities was CNY 28,560,809.00, a decrease from CNY 35,360,785.00 in the previous year, reflecting a decline of approximately 19.9%[26] - The net cash flow from financing activities was -CNY 7,174,678.16, compared to -CNY 23,257,853.78 in the same period of 2023, indicating a reduced outflow[26] Assets and Liabilities - Total assets increased by 8.78% to CNY 492,896,698.71 as of September 30, 2024, compared to CNY 453,093,129.65 at the end of 2023[4] - The company's current assets decreased from 294,402,629.11 yuan at the end of 2023 to 234,863,474.45 yuan, a decline of about 20.2%[15] - The company's total liabilities increased from 59,718,298.80 yuan to 83,114,169.44 yuan, reflecting a rise of about 39.2%[17] - The company’s non-current liabilities totaled 5,229,200.38 yuan, up from 3,874,085.13 yuan, indicating an increase of approximately 35%[17] - The company’s equity attributable to shareholders rose from 393,209,412.92 yuan to 409,173,051.30 yuan, an increase of approximately 4.1%[17] - The accounts receivable increased from 63,263,660.23 yuan to 79,838,351.47 yuan, representing a growth of about 26.3%[15] - The company's inventory increased slightly from 73,931,694.95 yuan to 74,678,189.19 yuan, a growth of about 1%[15] Expenses - Sales expenses surged by 157.66% to ¥2,928,687.34, resulting from an increase in sales personnel and participation in more domestic and international exhibitions[6] - Management expenses grew by 75.81% to ¥10,447,827.51, primarily due to salary increases for management and additional personnel in the U.S. subsidiary[6] - Research and development expenses for the first nine months of 2024 were ¥9,025,240.80, a decrease of 16.0% compared to ¥10,729,104.02 in the same period of 2023[21] - The company reported a credit impairment loss of ¥1,140,300.91 for the first nine months of 2024, compared to a gain of ¥212,535.09 in 2023[23] - The company incurred asset impairment losses of ¥2,002,103.30 in the first nine months of 2024, compared to ¥478,285.04 in 2023, indicating a significant increase in losses[23] Future Plans - The company plans to apply for a credit line of up to 120 million yuan from banks, with actual control and major shareholders providing guarantees as needed[13] - The company plans to expand its market presence and invest in new product development to drive future growth[21]

证券代码：833230 证券简称：欧康医药 公告编号：2024-092 成都欧康医药股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席顾兵 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规章 等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 根据《公司法》、《证券法》、《北京证券交易所上市公司持续监管指引第 2 号——季度报告》的规定，公司组织编制了《2024 年三季度报告》。 具体内容详见公司于 2024 年 10 月 30 日在北京证券交易所信息披露平台 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：202 ...